HELIOS GALLEGO-GUTIERREZ

Dr. HELIOS GALLEGO-GUTIERREZ

Life Sciences Institute, University of Michigan–Ann Arbor, Ann Arbor, Michigan, USA
orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
LGLorenza González-Mariscal
Lorenza González-Mariscal
HGHELIOS GALLEGO-GUTIERREZ
HELIOS GALLEGO-GUTIERREZ
LGLaura González-González
Laura González-González
CHChristian Hernández-Guzmán
Christian Hernández-Guzmán
ZO-2 is a cytoplasmic protein of tight junctions (TJs). Here, we describe ZO-2 involvement in the formation of the apical junctional complex during early development and in TJ biogenesis in epithelial cultured cells. ZO-2 acts as a scaffold for the polymerization of claudins at TJs and plays a unique role in the blood–testis barrier, as well as at TJs of the human liver and the inner ear. ZO-2 movement between the cytoplasm and nucleus is regulated by nuclear localization and exportation signals and post-translation modifications, while ZO-2 arrival at the cell border is triggered by activation of calcium sensing receptors and corresponding downstream signaling. Depending on its location, ZO-2 associates with junctional proteins and the actomyosin cytoskeleton or a variety of nuclear proteins, playing a role as a transcriptional repressor that leads to inhibition of cell proliferation and transformation. ZO-2 regulates cell architecture through modulation of Rho proteins and its absence induces hypertrophy due to inactivation of the Hippo pathway and activation of mTOR and S6K. The interaction of ZO-2 with viral oncoproteins and kinases and its silencing in diverse carcinomas reinforce the view of ZO-2 as a tumor regulator protein.

11 November 2022 in Circulation Research
Verified
Journal Article
Closed access
PDF file
CLCatherine Chinhchu Lai
Catherine Chinhchu Lai
BNBliss Nelsen
Bliss Nelsen
EFEduardo Frias-Anaya
Eduardo Frias-Anaya
HGHELIOS GALLEGO-GUTIERREZ
HELIOS GALLEGO-GUTIERREZ
MOMarco C. Orecchioni
Marco C. Orecchioni
MLMiguel Alejandro Lopez-Ramirez
Miguel Alejandro Lopez-Ramirez
Background: Cerebral cavernous malformations (CCMs) are neurovascular lesions caused by loss of function mutations in 1 of 3 genes, including KRIT1 (CCM1 ), CCM2 , and PDCD10 (CCM3 ). CCMs affect ≈1 out of 200 children and adults, and no pharmacologic therapy is available. CCM lesion count, size, and aggressiveness vary widely among patients of similar ages with the same mutation or even within members of the same family. However, what determines the transition from quiescent lesions into mature and active (aggressive) CCM lesions is unknown. Methods: We use genetic, RNA-sequencing, histology, flow cytometry, and imaging techniques to report the interaction between CCM endothelium, astrocytes, leukocytes, microglia/macrophages, neutrophils (CCM endothelium, astrocytes, leukocytes, microglia/macrophages, neutrophils interaction) during the pathogenesis of CCMs in the brain tissue. Results: Expression profile of astrocytes in adult mouse brains using translated mRNAs obtained from the purification of EGFP (enhanced green fluorescent protein)-tagged ribosomes ( Aldh1l1-EGFP/Rpl10a ) in the presence or absence of CCM lesions ( Slco1c1-iCreERT2;Pdcd10 fl/fl ; Pdcd10 BECKO ) identifies a novel gene signature for neuroinflammatory astrocytes. CCM-induced reactive astrocytes have a neuroinflammatory capacity by expressing genes involved in angiogenesis, chemotaxis, hypoxia signaling, and inflammation. RNA-sequencing analysis on RNA isolated from brain endothelial cells in chronic Pdcd10 BECKO mice (CCM endothelium), identified crucial genes involved in recruiting inflammatory cells and thrombus formation through chemotaxis and coagulation pathways. In addition, CCM endothelium was associated with increased expression of Nlrp3 and Il1b . Pharmacological inhibition of NLRP3 (NOD [nucleotide-binding oligomerization domain]-‚ LRR [leucine-rich repeat]- and pyrin domain-containing protein 3) significantly decreased inflammasome activity as assessed by quantification of a fluorescent indicator of caspase-1 activity (FAM-FLICA [carboxyfluorescein-fluorochrome-labeled inhibitors of caspases] caspase-1) in brain endothelial cells from Pdcd10 BECKO in chronic stage. Importantly, our results support the hypothesis of the crosstalk between astrocytes and CCM endothelium that can trigger recruitment of inflammatory cells arising from brain parenchyma (microglia) and the peripheral immune system (leukocytes) into mature active CCM lesions that propagate lesion growth, immunothrombosis, and bleedings. Unexpectedly, partial or total loss of brain endothelial NF-κB (nuclear factor κB) activity (using Ikkb fl/fl mice) in chronic Pdcd10 BECKO mice does not prevent lesion genesis or neuroinflammation. Instead, this resulted in a trend increase in the number of lesions and immunothrombosis, suggesting that therapeutic approaches designed to target inflammation through endothelial NF-κB inhibition may contribute to detrimental side effects. Conclusions: Our study reveals previously unknown links between neuroinflammatory astrocytes and inflamed CCM endothelium as contributors that trigger leukocyte recruitment and precipitate immunothrombosis in CCM lesions. However, therapeutic approaches targeting brain endothelial NF-κB activity may contribute to detrimental side effects.

15 May 2016 in Molecular Biology of the Cell
Verified
Journal Article
Open access
PDF file
ADAlaide Domínguez-Calderón
Alaide Domínguez-Calderón
AÁAntonia Ávila-Flores
Antonia Ávila-Flores
APArturo Ponce
Arturo Ponce
ELEsther Lopez-Bayghen
Esther Lopez-Bayghen
JCJosé-Víctor Calderón-Salinas
José-Víctor Calderón-Salinas
LGLorenza González-Mariscal
Lorenza González-Mariscal
Renal compensatory hypertrophy (RCH) restores normal kidney function after disease or loss of kidney tissue, and is characterized by an increase in organ size due to cell enlargement and not to cell proliferation. In renal epithelial cells MDCK, silencing of the tight junction protein Zona occludens 2 (ZO-2 KD), induces cell hypertrophy by two mechanisms: prolonging the time that cells spend at the G1 phase of the cell cycle, due to an increase in cyclin D1 level; and augmenting the rate of protein synthesis. The latter is triggered by the nuclear accumulation and increased transcriptional activity of YAP (Yes-associated protein), the main target of the Hippo pathway, which results in the decreased expression of PTEN (phosphate and tensin homologue). This in turn, increased the level of PIP3 [phosphatidylinositol (3,4,5)-triphosphate] that transactivates the Akt/mTOR (mammalian target of rapamycin) pathway, leading to the activation of the kinase S6K1 and to an increased synthesis of proteins and cell size. In agreement, in a rat model of uninephrectomy, RCH is accompanied by a decreased expression of ZO-2 and the nuclear expression of YAP. Our results reveal a novel role of ZO-2 as a modulator of cell size.

1 September 2020 in Biochimica et Biophysica Acta (BBA) - Biomembranes
Verified
Journal Article
Closed access
LGLorenza González-Mariscal
Lorenza González-Mariscal
JMJael Miranda
Jael Miranda
HGHELIOS GALLEGO-GUTIERREZ
HELIOS GALLEGO-GUTIERREZ
MCMisael Cano-Cortina
Misael Cano-Cortina
EAElida Amaya
Elida Amaya

1 June 2024 in Arteriosclerosis, Thrombosis, and Vascular Biology
Verified
Journal Article
Closed access
EFEduardo Frias-Anaya
Eduardo Frias-Anaya
HGHELIOS GALLEGO-GUTIERREZ
HELIOS GALLEGO-GUTIERREZ
BGBrendan Gongol
Brendan Gongol
SWShantel Weinsheimer
Shantel Weinsheimer
CLCatherine Chinhchu Lai
Catherine Chinhchu Lai
MLMiguel Alejandro Lopez-Ramirez
Miguel Alejandro Lopez-Ramirez
BACKGROUND: Heterogeneity in the severity of cerebral cavernous malformations (CCMs) disease, including brain bleedings and thrombosis that cause neurological disabilities in patients, suggests that environmental, genetic, or biological factors act as disease modifiers. Still, the underlying mechanisms are not entirely understood. Here, we report that mild hypoxia accelerates CCM disease by promoting angiogenesis, neuroinflammation, and vascular thrombosis in the brains of CCM mouse models. METHODS: We used genetic studies, RNA sequencing, spatial transcriptome, micro–computed tomography, fluorescence-activated cell sorting, multiplex immunofluorescence, coculture studies, and imaging techniques to reveal that sustained mild hypoxia via the CX3CR1-CX3CL1 (CX3C motif chemokine receptor 1/chemokine [CX3C motif] ligand 1) signaling pathway influences cell-specific neuroinflammatory interactions, contributing to heterogeneity in CCM severity. RESULTS: Histological and expression profiles of CCM neurovascular lesions ( Slco1c1-iCreERT2;Pdcd10 fl/fl ; Pdcd10 BECKO ) in male and female mice found that sustained mild hypoxia (12% O 2 , 7 days) accelerates CCM disease. Our findings indicate that a small reduction in oxygen levels can significantly increase angiogenesis, neuroinflammation, and thrombosis in CCM disease by enhancing the interactions between endothelium, astrocytes, and immune cells. Our study indicates that the interactions between CX3CR1 and CX3CL1 are crucial in the maturation of CCM lesions and propensity to CCM immunothrombosis. In particular, this pathway regulates the recruitment and activation of microglia and other immune cells in CCM lesions, which leads to lesion growth and thrombosis. We found that human CX3CR1 variants are linked to lower lesion burden in familial CCMs, proving it is a genetic modifier in human disease and a potential marker for aggressiveness. Moreover, monoclonal blocking antibody against CX3CL1 or reducing 1 copy of the Cx3cr1 gene significantly reduces hypoxia-induced CCM immunothrombosis. CONCLUSIONS: Our study reveals that interactions between CX3CR1 and CX3CL1 can modify CCM neuropathology when lesions are accelerated by environmental hypoxia. Moreover, a hypoxic environment or hypoxia signaling caused by CCM disease influences the balance between neuroinflammation and neuroprotection mediated by CX3CR1-CX3CL1 signaling. These results establish CX3CR1 as a genetic marker for patient stratification and a potential predictor of CCM aggressiveness.

15 July 2021 in Molecular Biology of the Cell
Verified
Journal Article
Open access
HGHELIOS GALLEGO-GUTIERREZ
HELIOS GALLEGO-GUTIERREZ
LGLaura González-González
Laura González-González
LRLeticia Ramírez-Martínez
Leticia Ramírez-Martínez
ELEsther López-Bayghen
Esther López-Bayghen
LGLorenza González-Mariscal
Lorenza González-Mariscal
ZO-2 interaction with TEAD regulates TEAD movement in and out of the nucleus. nPKCδ blocks formation of ZO-2/TEAD complex. PKA blocks ZO-2 nuclear import. nPKCε activates a NES of ZO-2 and TEAD exportation in a complex with ZO-2 or alone.